A bi-functional antibody-receptor domain fusion protein simultaneously targeting IGF-IR and VEGF for degradation

References

• Chames P, Baty D. Bispecific antibodies for cancer therapy: the light at the end of the tunnel? mAbs 2009; 1:539-47; PMID:20073127; http://dx.doi.org/10.4161/mabs.1.6.10015
   PubMed Web of Science ®Google Scholar
• Kontermann RE, Brinkmann U. Bispecific antibodies. Drug Dis Today 2015; PMID:25728220
   PubMed Web of Science ®Google Scholar
• Linke R, Klein A, Seimetz D. Catumaxomab: clinical development and future directions. mAbs 2010; 2:129-36; PMID:20190561; http://dx.doi.org/10.4161/mabs.2.2.11221
   PubMed Web of Science ®Google Scholar
• Dong J, Demarest SJ, Sereno A, Tamraz S, Langley E, Doern A, Snipas T, Perron K, Joseph I, Glaser SM, et al. Combination of two insulin-like growth factor-I receptor inhibitory antibodies targeting distinct epitopes leads to an enhanced antitumor response. Mol Cancer Ther 2010; 9:2593-604; PMID:20716637; http://dx.doi.org/10.1158/1535-7163.MCT-09-1018
   PubMed Web of Science ®Google Scholar
• Lu D, Zhang H, Ludwig D, Persaud A, Jimenez X, Burtrum D, Balderes P, Liu M, Bohlen P, Witte L, et al. Simultaneous blockade of both the epidermal growth factor receptor and the insulin-like growth factor receptor signaling pathways in cancer cells with a fully human recombinant bispecific antibody. J Biol Chem 2004; 279:2856-65; PMID:14576153; http://dx.doi.org/10.1074/jbc.M310132200
   PubMed Web of Science ®Google Scholar
• Jordan JL, Arndt JW, Hanf K, Li G, Hall J, Demarest S, Huang F, Wu X, Miller B, Glaser S, et al. Structural understanding of stabilization patterns in engineered bispecific Ig-like antibody molecules. Proteins 2009; 77:832-41; PMID:19626705; http://dx.doi.org/10.1002/prot.22502
   PubMed Web of Science ®Google Scholar
• Davis JH, Aperlo C, Li Y, Kurosawa E, Lan Y, Lo KM, Huston JS. SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies. Protein Eng, Des Sel 2010; 23:195-202; http://dx.doi.org/10.1093/protein/gzp094
   PubMed Web of Science ®Google Scholar
• Mabry R, Gilbertson DG, Frank A, Vu T, Ardourel D, Ostrander C, Stevens B, Julien S, Franke S, Meengs B, et al. A dual-targeting PDGFRbeta/VEGF-A molecule assembled from stable antibody fragments demonstrates anti-angiogenic activity in vitro and in vivo. mAbs 2010; 2:20-34; PMID:20065654; http://dx.doi.org/10.4161/mabs.2.1.10498
   PubMed Web of Science ®Google Scholar
• Mabry R, Lewis KE, Moore M, McKernan PA, Bukowski TR, Bontadelli K, Brender T, Okada S, Lum K, West J, et al. Engineering of stable bispecific antibodies targeting IL-17A and IL-23. Protein Eng Des Sel 2010; 23:115-27; http://dx.doi.org/10.1093/protein/gzp073
   PubMed Web of Science ®Google Scholar
• Miller BR, Demarest SJ, Lugovskoy A, Huang F, Wu X, Snyder WB, Croner LJ, Wang N, Amatucci A, Michaelson JS, et al. Stability engineering of scFvs for the development of bispecific and multivalent antibodies. Protein Eng Des Sel 2010; 23:549-57; http://dx.doi.org/10.1093/protein/gzq028
   PubMed Web of Science ®Google Scholar
• Schaefer G, Haber L, Crocker LM, Shia S, Shao L, Dowbenko D, Totpal K, Wong A, Lee CV, Stawicki S, et al. A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies. Cancer Cell 2011; 20:472-86; PMID:22014573; http://dx.doi.org/10.1016/j.ccr.2011.09.003
   PubMed Web of Science ®Google Scholar
• Lewis SM, Wu X, Pustilnik A, Sereno A, Huang F, Rick HL, Guntas G, Leaver-Fay A, Smith EM, Ho C, et al. Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface. Nat Biotechnol 2014; 32:191-8; PMID:24463572; http://dx.doi.org/10.1038/nbt.2797
   PubMed Web of Science ®Google Scholar
• Von Kreudenstein TS, Escobar-Carbrera E, Lario PI, D'Angelo I, Brault K, Kelly J, Durocher Y, Baardsnes J, Woods RJ, Xie MH, et al. Improving biophysical properties of a bispecific antibody scaffold to aid developability: quality by molecular design. mAbs 2013; 5:646-54; PMID:23924797; http://dx.doi.org/10.4161/mabs.25632
   PubMed Web of Science ®Google Scholar
• Schaefer W, Regula JT, Bahner M, Schanzer J, Croasdale R, Durr H, Gassner C, Georges G, Kettenberger H, Imhof-Jung S, et al. Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proc Natl Acad Sci U S A 2011; 108:11187-92; PMID:21690412; http://dx.doi.org/10.1073/pnas.1019002108
   PubMed Web of Science ®Google Scholar
• Labrijn AF, Meesters JI, de Goeij BE, van den Bremer ET, Neijssen J, van Kampen MD, Strumane K, Verploegen S, Kundu A, Gramer MJ, et al. Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange. Proc Natl Acad Sci U S A 2013; 110:5145-50; PMID:23479652; http://dx.doi.org/10.1073/pnas.1220145110
   PubMed Web of Science ®Google Scholar
• List T, Neri D. Immunocytokines: a review of molecules in clinical development for cancer therapy. Clin Pharmacol 2013; 5:29-45; PMID:23990735
   PubMedGoogle Scholar
• Ferrara N. VEGF-A: a critical regulator of blood vessel growth. Eur Cytokine Netw 2009; 20:158-63; PMID:20167554
   PubMed Web of Science ®Google Scholar
• Gerber HP, Hillan KJ, Ryan AM, Kowalski J, Keller GA, Rangell L, Wright BD, Radtke F, Aguet M, Ferrara N. VEGF is required for growth and survival in neonatal mice. Development 1999; 126:1149-59; PMID:10021335
   PubMed Web of Science ®Google Scholar
• Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005; 23:1011-27; PMID:15585754; http://dx.doi.org/10.1200/JCO.2005.06.081
   PubMed Web of Science ®Google Scholar
• Senger DR, Van de Water L, Brown LF, Nagy JA, Yeo KT, Yeo TK, Berse B, Jackman RW, Dvorak AM, Dvorak HF. Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Reviews 1993; 12:303-24; PMID:8281615; http://dx.doi.org/10.1007/BF00665960
   PubMed Web of Science ®Google Scholar
• Claesson-Welsh L. Healing hemangiomas. Nat Med 2008; 14:1147-8; PMID:18989275; http://dx.doi.org/10.1038/nm1108-1147
   PubMed Web of Science ®Google Scholar
• Wiesmann C, Fuh G, Christinger HW, Eigenbrot C, Wells JA, de Vos AM. Crystal structure at 1.7 A resolution of VEGF in complex with domain 2 of the Flt-1 receptor. Cell 1997; 91:695-704; PMID:9393862; http://dx.doi.org/10.1016/S0092-8674(00)80456-0
   PubMed Web of Science ®Google Scholar
• Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M, Boland P, Leidich R, Hylton D, Burova E, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A 2002; 99:11393-8; PMID:12177445; http://dx.doi.org/10.1073/pnas.172398299
   PubMed Web of Science ®Google Scholar
• Burtrum D, Zhu Z, Lu D, Anderson DM, Prewett M, Pereira DS, Bassi R, Abdullah R, Hooper AT, Koo H, et al. A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. Cancer Res 2003; 63:8912-21; PMID:14695208
   PubMed Web of Science ®Google Scholar
• Rowinsky EK, Youssoufian H, Tonra JR, Solomon P, Burtrum D, Ludwig DL. IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor. Clin Cancer Res 2007; 13:5549s-55s; PMID:17875788; http://dx.doi.org/10.1158/1078-0432.CCR-07-1109
   PubMed Web of Science ®Google Scholar
• Yap TA, Olmos D, Molife LR, de Bono JS. Targeting the insulin-like growth factor signaling pathway: figitumumab and other novel anticancer strategies. Exp Opin Investig Drugs 2011; 20:1293-304; PMID:21777167; http://dx.doi.org/10.1517/13543784.2011.602630
   PubMed Web of Science ®Google Scholar
• Li H, Adachi Y, Yamamoto H, Min Y, Ohashi H, Ii M, Arimura Y, Endo T, Lee CT, Carbone DP, et al. Insulin-like growth factor-I receptor blockade reduces tumor angiogenesis and enhances the effects of bevacizumab for a human gastric cancer cell line, MKN45. Cancer 2011; 117:3135-47; PMID:21264842; http://dx.doi.org/10.1002/cncr.25893
   PubMed Web of Science ®Google Scholar
• Reinmuth N, Liu W, Fan F, Jung YD, Ahmad SA, Stoeltzing O, Bucana CD, Radinsky R, Ellis LM. Blockade of insulin-like growth factor I receptor function inhibits growth and angiogenesis of colon cancer. Clin Cancer Res 2002; 8:3259-69; PMID:12374697
   PubMed Web of Science ®Google Scholar
• Spiliotaki M, Markomanolaki H, Mela M, Mavroudis D, Georgoulias V, Agelaki S. Targeting the insulin-like growth factor I receptor inhibits proliferation and VEGF production of non-small cell lung cancer cells and enhances paclitaxel-mediated anti-tumor effect. Lung Cancer 2011; 73:158-65; PMID:21190751; http://dx.doi.org/10.1016/j.lungcan.2010.11.010
   PubMed Web of Science ®Google Scholar
• Feldser D, Agani F, Iyer NV, Pak B, Ferreira G, Semenza GL. Reciprocal positive regulation of hypoxia-inducible factor 1alpha and insulin-like growth factor 2. Cancer Res 1999; 59:3915-8; PMID:10463582
   PubMed Web of Science ®Google Scholar
• Kim KW, Bae SK, Lee OH, Bae MH, Lee MJ, Park BC. Insulin-like growth factor II induced by hypoxia may contribute to angiogenesis of human hepatocellular carcinoma. Cancer Res 1998; 58:348-51; PMID:9443416
   PubMed Web of Science ®Google Scholar
• Harding TC, Long L, Palencia S, Zhang H, Sadra A, Hestir K, Patil N, Levin A, Hsu AW, Charych D, et al. Blockade of nonhormonal fibroblast growth factors by FP-1039 inhibits growth of multiple types of cancer. Sci Transl Med 2013; 5:178ra39; PMID:23536011; http://dx.doi.org/10.1126/scitranslmed.3005414
   PubMed Web of Science ®Google Scholar
• Ferrara N, Chen H, Davis-Smyth T, Gerber HP, Nguyen TN, Peers D, Chisholm V, Hillan KJ, Schwall RH. Vascular endothelial growth factor is essential for corpus luteum angiogenesis. Nat Med 1998; 4:336-40; PMID:9500609; http://dx.doi.org/10.1038/nm0398-336
   PubMed Web of Science ®Google Scholar
• Gerber HP, Vu TH, Ryan AM, Kowalski J, Werb Z, Ferrara N. VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat Med 1999; 5:623-8; PMID:10371499; http://dx.doi.org/10.1038/9467
   PubMed Web of Science ®Google Scholar
• Sullivan LA, Brekken RA. The VEGF family in cancer and antibody-based strategies for their inhibition. mAbs 2010; 2:165-75; PMID:20190566; http://dx.doi.org/10.4161/mabs.2.2.11360
   PubMed Web of Science ®Google Scholar
• Falcon BL, O'Clair B, McClure D, Evans GF, Stewart J, Swearingen ML, Chen Y, Allard K, Lee LN, Neote K, et al. Development and characterization of a high-throughput in vitro cord formation model insensitive to VEGF inhibition. J Hematol Oncol 2013; 6:31; PMID:23622716; http://dx.doi.org/10.1186/1756-8722-6-31
   PubMed Web of Science ®Google Scholar
• Rudge JS, Holash J, Hylton D, Russell M, Jiang S, Leidich R, Papadopoulos N, Pyles EA, Torri A, Wiegand SJ, et al. VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade. Proc Natl Acad Sci U S A 2007; 104:18363-70; PMID:18000042; http://dx.doi.org/10.1073/pnas.0708865104
   PubMed Web of Science ®Google Scholar
• Witte L, Hicklin DJ, Zhu Z, Pytowski B, Kotanides H, Rockwell P, Bohlen P. Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy. Cancer Metastasis Rev 1998; 17:155-61; PMID:9770111; http://dx.doi.org/10.1023/A:1006094117427
   PubMed Web of Science ®Google Scholar
• Shen Y, Zeng L, Zhu A, Blanc T, Patel D, Pennello A, Bari A, Ng S, Persaud K, Kang YK, et al. Removal of a C-terminal serine residue proximal to the inter-chain disulfide bond of a human IgG1 lambda light chain mediates enhanced antibody stability and antibody dependent cell-mediated cytotoxicity. mAbs 2013; 5:418-31; PMID:23567210; http://dx.doi.org/10.4161/mabs.24291
   PubMed Web of Science ®Google Scholar
• Yang Y, Zhang Y, Cao Z, Ji H, Yang X, Iwamoto H, Wahlberg E, Lanne T, Sun B, Cao Y. Anti-VEGF- and anti-VEGF receptor-induced vascular alteration in mouse healthy tissues. Proc Natl Acad Sci U S A 2013; 110:12018-23; PMID:23818623; http://dx.doi.org/10.1073/pnas.1301331110
   PubMed Web of Science ®Google Scholar
• Bogusz J, Majchrzak A, Medra A, Cebula-Obrzut B, Robak T, Smolewski P. Mechanisms of action of the anti-VEGF monoclonal antibody bevacizumab on chronic lymphocytic leukemia cells. Postepy Hig Med Dosw (Online) 2013; 67:107-18; PMID:23475487; http://dx.doi.org/10.5604/17322693.1038349
   PubMedGoogle Scholar
• Stefanini MO, Wu FT, Mac Gabhann F, Popel AS. Increase of plasma VEGF after intravenous administration of bevacizumab is predicted by a pharmacokinetic model. Cancer Res 2010; 70:9886-94; PMID:21118974; http://dx.doi.org/10.1158/0008-5472.CAN-10-1419
   PubMed Web of Science ®Google Scholar
• Bottos A, Martini M, Di Nicolantonio F, Comunanza V, Maione F, Minassi A, Appendino G, Bussolino F, Bardelli A. Targeting oncogenic serine/threonine-protein kinase BRAF in cancer cells inhibits angiogenesis and abrogates hypoxia. Proc Natl Acad Sci U S A 2012; 109:E353-9; PMID:22203991; http://dx.doi.org/10.1073/pnas.1105026109
   PubMed Web of Science ®Google Scholar
• Igawa T, Maeda A, Haraya K, Tachibana T, Iwayanagi Y, Mimoto F, Higuchi Y, Ishii S, Tamba S, Hironiwa N, et al. Engineered monoclonal antibody with novel antigen-sweeping activity in vivo. PloS one 2013; 8:e63236; PMID:23667591; http://dx.doi.org/10.1371/journal.pone.0063236
   PubMed Web of Science ®Google Scholar
• Kang YK, Hamzik J, Felo M, Qi B, Lee J, Ng S, Liebisch G, Shanehsaz B, Singh N, Persaud K, et al. Development of a novel and efficient cell culture flocculation process using a stimulus responsive polymer to streamline antibody purification processes. Biotechnol Bioeng 2013; 110:2928-37; PMID:23740533; http://dx.doi.org/10.1002/bit.24969
   PubMed Web of Science ®Google Scholar